
|Articles|February 15, 2016
AMA guidelines for social media use
The American Medical Association adopted 7 policies on professionalism you need to know when using social media.
Advertisement
The American Medical Association (AMA) adopted a policy on professionalism when using social media in late 2010. The policy, according to the AMA, is aimed at helping physicians to “maintain a positive online presence and preserve the integrity of the patient-physician relationship.”
Among the policy’s recommendations:
- Refrain from posting identifiable patient information online.
- Use privacy settings to safeguard personal information and content to the fullest extent possible on social networking sites. But realize that privacy settings are not absolute and internet content is likely permanent.
- Routinely monitor your Internet presence to ensure that your personal and professional information on your sites and those operated by others is accurate and appropriate.
- Maintain appropriate boundaries of the patient-physician relationship when interacting with patients online and ensure that patient privacy and confidentiality is maintained.
- Consider separating personal and professional content online.
- If you see content posted by colleagues that appears unprofessional, you are responsible for bringing the content to the attention of the individual who posted it, so that he or she can remove it or take other appropriate actions. “If the behavior significantly violates professional norms and the individual does not take appropriate action to resolve the situation, the physician should report the matter to appropriate authorities,” according to the AMA. Those authorities include local medical boards, state or federal lawmakers and regulators or hospital boards, according to the AMA.
- Understand that your online actions (including the content you post) can negatively impact your reputation among patients and colleagues, and could have negative consequences for your medical career.
For complete guidelines:
More on social media
Advertisement
Related to this article

Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.

The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.

The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.

Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.

Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.

Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.

New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
2
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
3
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
4
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
5


